Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

FDA approves Kesimpta for the treatment of relapsing multiple sclerosis

Aug. 21, 2020

Esteve presents dual sigma1 and mu-opioid receptor ligands

Aug. 21, 2020

New opioid receptor ligands identified at Yangtze River Pharmaceutical

Aug. 21, 2020

Shionogi describes identification of clinical candidate P2X3 receptor antagonist S-600918

Aug. 20, 2020

Taisho details antidepressant potential of V1b receptor antagonist THY-1773

Aug. 20, 2020

University of Queensland, Preveceutical Medical patent delta- and kappa-opioid receptor antagonists

Aug. 19, 2020

Discovery of a novel FASN inhibitor with promising activity in model of AD

Aug. 19, 2020

Targeting nuclear transport protein could lead to opioid alternatives

Aug. 18, 2020

CSPC Zhongqi Pharmaceutical Technology describes PROTAC BRD4 degradation inducers

Aug. 18, 2020

New CACNA2D ligands discovered at Sichuan Haisco Pharmaceutical

Aug. 18, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...